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Interactions between left
ventricular ejection fraction,
sex and effect of
neurohumoral modulators
in heart failure
Recently, the Prospective Comparison of
ARNI (angiotensin receptor–neprilysin
inhibitor) with ARB (angiotensin recep-
tor blocker) Global Outcomes in Heart
Failure with Preserved Ejection Fraction
(PARAGON-HF) trial suggested that women
might obtain more benefit than men from
sacubitril/valsartan, compared with valsartan,
in heart failure with preserved ejection frac-
tion (HFpEF).1–3 However, the picture is more
complicated as there was also an interaction
between left ventricular ejection fraction
(LVEF) and the effect of sacubitril/valsartan.2
Patients with a LVEF at or below the median
(57%) seemed to gain more benefit from
sacubitril/valsartan than those with a LVEF
above the median.2 To make matters more
complex still, it is well known that the dis-
tribution of LVEF is different in women and
men, with women, on average, having a higher
LVEF than men, be it in the general population
or in individuals with heart failure (HF).4–6
Despite a higher LVEF, women with HFpEF
had worse systolic function, as assessed by
tissue Doppler echocardiography, compared
to men with HFpEF.7 To further investigate
the relationship between sex, LVEF and treat-
ment in HF, we explored the effect of three
different neurohumoral modulators in large
trials which provide data on clinical outcomes
in patients with HF, across the full range
of LVEF, incorporating the three commonly
described HF phenotypes – HF with reduced
ejection fraction (HFrEF, LVEF <40%), HFpEF
(LVEF >50%) and HF with mid-range ejection
fraction (HFmrEF, LVEF 40–50%).8
We pooled individual patient-level data
from: (i) three trials using an angiotensin
receptor blocker – the Candesartan in
Heart failure: Assessment of Reduction in
Mortality and morbidity (CHARM) – the
CHARM-Alternative and CHARM-Added
trials in HFrEF and the CHARM-Preserved
trial in HFmrEF/HFpEF;9 (ii) three trials using
a mineralocorticoid receptor antagonist
(MRA) – two HFrEF trials, the Randomized
Aldactone Evaluation Study (RALES) and
the Eplerenone in Mild Patients Hospital-
ization and Survival Study in Heart Failure
(EMPHASIS-HF), and one HFmrEF/HFpEF
trial – the Treatment of Preserved Cardiac
Function Heart Failure with an Aldos-
terone Antagonist trial (TOPCAT).10–12
Only TOPCAT patients from the Amer-
icas were included; (iii) two trials using
sacubitril/valsartan – the Prospective Com-
parison of ARNI with ACEI to Determine
Impact on Global Mortality and Morbidity
in HF trial (PARADIGM-HF) in HFrEF and
PARAGON-HF in HFmrEF/HFpEF.1,13
Cox proportional hazards modelling was
used to analyse (i) the primary composite
outcome (first occurrence of HF hospital-
ization or cardiovascular death); (ii) first HF
hospitalization; and (iii) cardiovascular death.
Likelihood ratio tests were used to report (i)
two-way interaction between treatment and
sex; and (ii) three-way interaction between
treatment, sex and LVEF. LVEF, modelled as a
fractional polynomial, and its interaction with
treatment using the best fit model for each
drug category (based on the primary com-
posite outcome) was examined with the mfpi
command in Stata. Models were stratified by
trial for MRAs and sacubitril/valsartan. All
analyses were conducted using Stata version
16 (Stata Corp., College Station, TX, USA).
This present analysis included 2400, 1938
and 4311 women and 5199, 4229 and 8884
men in the candesartan, MRA and sacubi-
tril/valsartan trials, respectively (Table 1).
Overall mean LVEF (%) was 38.9±14.9%,
35.3±16.0% and 39.7± 15.1%, respectively.
Women had a higher mean LVEF, with the
difference compared to men 6.3%, 9.4% and
10.3%, respectively. Women had a lower
incidence of the primary composite outcome
(and its components) in each of the treatment
and control groups.
In keeping with prior reports from the
CHARM Programme and TOPCAT, as well
as a recent analysis of PARADIGM-HF and
PARAGON-HF, we found that treatment with
an ARB, MRA or ARNI may be of benefit
beyond the upper limit of LVEF eligibility
used in contemporary HFrEF clinical trials
(40%) and may extend to what has been
termed HFmrEF (LVEF 40–49%) and even to
the lower part of the LVEF range currently
categorized as HFpEF.2,6,14,15 Importantly, the
benefit of each treatment seemed to extend
to a higher LVEF in women, compared to
men (Figure 1). There was no difference in
efficacy of therapy between men and women
with HFrEF.
Because these are post hoc analyses, they
are only hypothesis generating. However, the
fact that all three neurohumoral modulating
therapies demonstrated the same sex-related
pattern of response raises the possibility that
the differential response between women
and men identified in PARAGON-HF may be
real rather than due to the play of chance,
although interpretation of PARAGON-HF is
more complex as it had an active comparator
compared with a placebo control in the other
trials. Despite this consistent observation in
the trials examined, the biological basis for
such a finding is uncertain. As detailed else-
where, the possibilities include sex-related
differences in cardiac remodelling in response
to blood pressure, age and other stimuli, and
differences in age-related arterial stiffening,
which is more pronounced in women than
men.3 Women may also have other evidence
of contractile dysfunction, compared with
men, for a given ejection fraction.3 Natri-
uretic peptide levels are lower in women with
HFpEF than in men, and women may have
reduced cyclic guanosine monophosphate-
protein kinase G signalling compared with
men, especially after the menopause.3 The
possibility that women with HF might benefit
from treatment to a higher level of LVEF than
previously considered could be of great clini-
cal importance. Women with HF have fewer
treatment options than men with HF because
HFmrEF and HFpEF are the predominant HF
phenotypes in women and no therapy has
been approved by regulatory authorities for
either of these phenotypes.6 More research
on this matter is clearly required.
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Table 1 Interaction of treatment and left ventricular ejection fraction in men and women with heart failure
Overall Men Women P-interactiona P-interactionb P-interactionc
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Candesartan
Patients, n 7599 5199 2400
Age, years, mean± SD 65.5±11.1 64.4±10.9 67.8±11.1
Ejection fraction, %, mean± SD 38.9±14.9 36.9±14.0 43.2±15.8
Primary composite outcome
Event rate per 100 pt. years (95% CI)
Placebo 13.8 (13.1–14.6) 14.3 (13.4–15.2) 12.9 (11.7–14.3)
Candesartan 11.6 (10.9–12.2) 11.9 (11.1–12.7) 10.8 (9.7–12.0)
Hazard ratio (95% CI) 0.84 (0.78–0.91) <0.001 0.84 (0.76–0.92) 0.84 (0.73–0.97) 0.9939 0.0146 0.0649
HF hospitalization
Event rate per 100 pt. years (95% CI)
Placebo 9.7 (9.1–10.3) 9.7 (9.0–10.5) 9.6 (8.6–10.8)
Candesartan 7.6 (7.1–8.2) 7.6 (7.0–8.3) 7.5 (6.6–8.6)
Hazard ratio (95% CI) 0.79 (0.72–0.87) <0.001 0.79 (0.70–0.89) 0.79 (0.66–0.94) 0.9824 0.0566 0.1361
Cardiovascular death
Event rate per 100 pt. years (95% CI)
Placebo 7.2 (6.7–7.7) 7.6 (7.0–8.3) 6.3 (5.5–7.2)
Candesartan 6.3 (5.9–6.8) 6.7 (6.2–7.4) 5.4 (4.7–6.2)
Hazard ratio (95% CI) 0.88 (0.79–0.97) 0.013 0.89 (0.79–1.00) 0.86 (0.70–1.04) 0.7531 0.3454 0.1876
MRA
Patients, n 6167 4229 1938
Age, years, mean± SD 68.5± 9.8 67.8± 9.6 70.1±10.1
Ejection fraction, %, mean± SD 35.3±16.0 32.3±14.0 41.7±18.1
Primary composite outcome
Event rate per 100 pt. years (95% CI)
Placebo 20.0 (18.8–21.2) 21.7 (20.2–23.3) 16.8 (15.0–18.7)
MRA 14.0 (13.1–15.0) 15.2 (14.0–16.4) 11.8 (10.5–13.4)
Hazard ratio (95% CI) 0.70 (0.64–0.77) <0.001 0.70 (0.63–0.77) 0.71 (0.60–0.84) 0.8089 0.0074 0.0682
HF hospitalization
Event rate per 100 pt. years (95% CI)
Placebo 13.9 (13.0–14.9) 14.8 (13.5–16.1) 12.3 (10.9–14.0)
MRA 9.4 (8.7–10.2) 9.9 (9.0–11.0) 8.4 (7.3–9.8)
Hazard ratio (95% CI) 0.69 (0.62–0.77) <0.001 0.68 (0.60–0.78) 0.70 (0.57–0.85) 0.8567 0.0077 0.1006
Cardiovascular death
Event rate per 100 pt. years (95% CI)
Placebo 9.7 (9.0–10.5) 10.8 (9.8–11.8) 7.6 (6.6–8.9)
MRA 7.0 (6.4–7.7) 8.1 (7.3–9.0) 5.1 (4.2–6.1)
Hazard ratio (95% CI) 0.73 (0.65–0.82) <0.001 0.75 (0.65–0.86) 0.67 (0.53–0.84) 0.4100 0.9333 0.9494
Sacubitril/valsartan
Patients, n 13 195 8884 4311
Age, years, mean± SD 67.0±11.3 65.6±11.3 70.0±10.6
Ejection fraction, %, mean± SD 39.7±15.1 36.3±13.4 46.6± 16.0
Primary composite outcome
Event rate per 100 pt. years (95% CI)
RAAS inhibitor 11.4 (10.8–11.9) 12.3 (11.6–13.0) 9.6 (8.8–10.5)
Sacubitril/valsartan 9.5 (9.1–10.0) 10.6 (9.9–11.2) 7.6 (6.9–8.4)
Hazard ratio (95% CI) 0.84 (0.78–0.90) <0.001 0.86 (0.79–0.93) 0.79 (0.70–0.91) 0.3452 0.0424 0.0034
HF hospitalization
Event rate per 100 pt. years (95% CI)
RAAS inhibitor 7.4 (7.0–7.9) 7.6 (7.1–8.2) 7.0 (6.3–7.8)
Sacubitril/valsartan 6.2 (5.9–6.6) 6.7 (6.2–7.3) 5.3 (4.7–5.9)
Hazard ratio (95% CI) 0.84 (0.77–0.92) <0.001 0.89 (0.80–0.98) 0.76 (0.65–0.88) 0.1003 0.0560 0.0057
Cardiovascular death
Event rate per 100 pt. years (95% CI)
RAAS inhibitor 5.6 (5.3–6.0) 6.6 (6.1–7.1) 3.8 (3.3–4.3)
Sacubitril/valsartan 4.7 (4.4–5.0) 5.4 (5.0–5.9) 3.3 (2.9–3.8)
Hazard ratio (95% CI) 0.83 (0.76–0.92) <0.001 0.81 (0.73–0.91) 0.89 (0.73–1.08) 0.4461 0.2136 0.5871
CI, confidence interval; HF, heart failure; MRA, mineralocorticoid receptor antagonist; RAAS, renin–angiotensin–aldosterone system; SD, standard deviation.
Hazard ratios were stratified for trial in case of MRA and sacubitril/valsartan.
aInteraction between treatment and sex.
bInteraction between treatment and ejection fraction modelled as a fractional polynomial.
cThree-way interaction between treatment, sex and ejection fraction.
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Figure 1 Variation of treatment effect with left ventricular ejection fraction in heart failure. Dotted curves show normalized distribution
of left ventricular ejection fraction (LVEF) in men and women. Solid lines show a continuous hazard ratio for the primary composite and its
components, according to treatment group in the range of LVEF included. The shaded areas represent the 95% confidence intervals. Primary
outcome (heart failure hospitalization/cardiovascular death): (A) candesartan vs. placebo; (B) mineralocorticoid receptor antagonist (MRA) vs.
placebo; (C) sacubitril/valsartan vs. renin–angiotensin–aldosterone system inhibitor. Heart failure hospitalization: (D) candesartan vs. placebo;
(E) MRA vs. placebo; (F) sacubitril/valsartan vs. renin–angiotensin–aldosterone system inhibitor. Cardiovascular death; (G) candesartan vs.
placebo; (H) MRA vs. placebo; (I) sacubitril/valsartan vs. renin–angiotensin–aldosterone system inhibitor.
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Eplerenone prevents
an increase in serum
carboxy-terminal propeptide





In the Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Sur-
vival Study (EPHESUS), eplerenone reduced
morbidity and mortality in patients who
had an acute myocardial infarction (MI),
complicated by systolic dysfunction, heart
failure (HF) or diabetes mellitus.1 In a pre-
specified secondary analysis of EPHESUS,
Iraqi et al.2 reported concomitant reductions
in the serum concentrations of N-terminal
propeptide of type I (PINP) and type III
(PIIINP) collagen, which may reflect an anti-
fibrotic effect of eplerenone; however, the
carboxy-terminal propeptide of procolla-
gen type I (PICP) was not analysed in that
report. Studies of endomyocardial biopsies
suggest that serum PIIINP and PICP (but not
PINP fragments) reflect myocardial fibrosis.3
Moreover, PICP originates directly from the
synthesis of collagen type I in a 1:1 ratio,
directly reflecting collagen type I synthesis.
On the other hand, PIIINP originates from
partially processed procollagen molecules on
the surface of collagen type III fibres. There-
fore, serum PIIINP may not accurately reflect
ongoing collagen type III synthesis. Further-
more, a net release from the heart into the
circulation has only been reported for PICP
(and not for PIIINP).4 Notwithstanding, for
no good reason, trials of mineralocorticoid
receptor antagonists (MRAs) have focused
more on PIIINP than on PICP.
The type of collagen as well as the amount
may be an important determinant of its
effects on myocardial function. Collagen
type I comprises highly cross-linked, large-
diameter fibres that have a major impact on
stiffness whereas collagen type III comprises
mainly non-cross-linked, small-diameter,
more pliable fibres.3 Whether eplerenone
also reduces serum PICP has not been
reported thus far.
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